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Aims: To evaluate the maintenance of efficacy and safety of insulin glargine 300 U/ml (Gla-300) versus glargine 100 U/ml (Gla-100) in people with type
2 diabetes mellitus (T2DM) using basal plus meal-time insulin for 12months in the EDITION 1 trial.
Methods: EDITION 1 was a multicentre, randomized, open-label, two-arm, phase IIIa study. Participants completing the initial 6-month treatment period
continued to receive Gla-300 or Gla-100, as previously randomized, once daily for a further 6-month open-label extension phase. Changes in glycated
haemoglobin (HbA1c) and fasting plasma glucose concentrations, insulin dose, hypoglycaemic events and body weight were assessed.
Results: Of 807 participants enrolled in the initial phase, 89% (359/404) assigned to Gla-300 and 88% (355/403) assigned to Gla-100 completed
12months. Glycaemic control was sustained in both groups (mean HbA1c: Gla-300, 7.24%; Gla-100, 7.42%), with more sustained HbA1c reduction for
Gla-300 at 12months: least squares mean difference Gla-300 vs Gla-100: HbA1c −0.17 [95% confidence interval (CI) −0.30 to −0.05]%. The mean daily
basal insulin dose at 12months was 1.03 U/kg for Gla-300 and 0.90 U/kg for Gla-100. Lower percentages of participants had ≥1 confirmed [≤3.9mmol/l
(≤70mg/dl)] or severe hypoglycaemic event with Gla-300 than Gla-100 at any time of day [24 h; 86 vs 92%; relative risk 0.94 (95% CI 0.89–0.99)]
and during the night [54 vs 65%; relative risk 0.84 (95% CI 0.75–0.94)], while the annualized rates of such hypoglycaemic events were similar. No
between-treatment differences in adverse events were apparent.
Conclusion: During 12months of treatment of T2DM requiring basal andmeal-time insulin, glycaemic control was better sustained and fewer individuals
reported hypoglycaemia with Gla-300 than with Gla-100. The mean basal insulin dose was higher with Gla-300 compared with Gla-100, but total numbers
of hypoglycaemic events and overall tolerability did not differ between treatments.
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Introduction
Control of hyperglycaemia becomes progressively more
difficult with increasing duration of type 2 diabetes mellitus
(T2DM). Despite optimized use of available therapies, includ-
ing insulin, some patients cannot attain or maintain desired
levels of glycaemic control [1,2]. Among the barriers to success
of insulin therapy are concerns about hypoglycaemia, injection
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frequency and weight gain [3,4]. Some of these difficulties
may be attributable to limitations of the profiles of action of
current basal insulins, and may become more apparent with
the progression of diabetes and prolonged treatment.
Compared with glargine 100U/ml (Gla-100), the new
insulin glargine 300U/ml formulation (Gla-300) has demon-
strated more prolonged and stable pharmacokinetic and
pharmacodynamic profiles, leading to glycaemic control
beyond 24 h after injection [5]. The phase IIIa EDITION
development programme was designed to determine whether
this improved profile of action would lead to better results in
clinical use. This programme compared the efficacy and safety
of Gla-300 with that of Gla-100 in people with T2DM using
basal-bolus insulin (EDITION 1) [6], people with T2DM using
basal insulin and oral antihyperglycaemic drugs (EDITION 2)
[7], and insulin-naïve people with T2DM (EDITION 3) [8].
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The 6-month results from these studies have shown similar
improvements in glycaemic control with intensified therapy
with Gla-300 and Gla-100, but lower rates of hypoglycaemia
with Gla-300. After 6months in EDITION 1, people previously
using basal and also meal-time insulin attained HbA1c values
close to 7.3% using each regimen, but with a 22% lower relative
risk of confirmed or severe nocturnal hypoglycaemia and no
increase in daytime hypoglycaemia with Gla-300 [6].
In a planned extension of the EDITION 1 trial, we exam-
ined whether the pattern of similar improvement of glycaemic
control with good tolerability and lower risk of nocturnal hypo-
glycaemia is maintained with continued use of Gla-300 for a
further 6-month interval of randomized but less intensively
supervised treatment.
Materials and Methods
Study Design and Population
This was a multicentre, open-label, two-arm parallel-group
study conducted between 15 December 2011 and 4 Septem-
ber 2013 in 13 countries (three in North America and nine
in Europe and South Africa) [6]. The study was registered
with ClinicalTrials.gov under the number NCT01499082. The
appropriate ethics committees approved the protocol and the
study was conducted according to Good Clinical Practice and
the Declaration of Helsinki. All participants provided written
informed consent.
Comprehensive details of the study design and participant
population have been reported previously [6]. In summary,
participants ≥18 years of age with T2DM (World Health Orga-
nization definition [9]) using basal insulin plus meal-time
insulin analogue were randomized (1 : 1) to receive once-daily
injections of either Gla-300 or Gla-100 with meal-time insulin.
Candidates were excluded if they used human meal-time
insulin or any premixed or basal insulin other than insulin
glargine or neutral protamine Hagedorn or had started using
new glucose-lowering agents and/or weight loss drugs in the
3months before the screening visit. Further details on exclu-
sion criteria have been reported previously [6]. As previously
described [6], once-daily injections of Gla-300 or Gla-100
in the evening were to be individually titrated once weekly
throughout the study following the same dosing recommen-
dations in both groups and seeking a fasting self-monitored
plasma glucose (SMPG) of 4.4–5.6mmol/l (80–100mg/dl).
Dose adjustments of both insulins were limited to 3-unit
increments or decrements because of the characteristics of the
pen injectors used. Meal-time insulin was to be adjusted at
the discretion of the site investigator based on SMPG data,
including, when appropriate, preprandial or 2-h postprandial
plasma glucose and consideration of the carbohydrate con-
tent of the meal, with the aim of optimizing glucose patterns
while limiting hypoglycaemia. Participants who completed the
6-month treatment period continued to receive either Gla-300
or Gla-100 according to initial randomization, along with their
meal-time insulin, for a further 6-month open-label extension
phase. After the 6-month visit, only one visit to the study site
(month 9) and two phone contacts (months 7.5 and 10.5) were
required for participants before their 12-month visit.
Efficacy and Safety Outcomes
At the end of the extension phase, the following efficacy
outcomes were assessed: change from baseline in glycaemic
control (HbA1c); fasting plasma glucose (FPG) and eight-point
SMPG profiles; mean insulin dose (basal and meal-time); and
treatment satisfaction scores (using the Diabetes Treatment
Satisfaction Questionnaire status version [DTSQs]). The
DTSQs addresses the participant’s satisfaction with treatment
(six items) as well as perceived hyperglycaemia (one item)
and perceived hypoglycaemia (one item) [10]. The safety
outcomes assessed included change from baseline in body
weight, the percentage of participants experiencing ≥1 hypo-
glycaemic event, annualized rates of hypoglycaemic events,
and the occurrence of other adverse events. All hypoglycaemic
events were categorized according to the American Diabetes
Association definitions [11]: (i) severe hypoglycaemia (an
event requiring the assistance of another person to actively
administer carbohydrate, glucagon or other resuscitative
actions); (ii) documented symptomatic hypoglycaemia [an
event during which typical symptoms of hypoglycaemia
are confirmed by a measured plasma glucose concentra-
tion of ≤3.9mmol/l (≤70mg/dl)]; and (iii) asymptomatic
hypoglycaemia confirmed by a measured plasma glucose con-
centration of ≤3.9mmol/l (≤70mg/dl). For the main analysis
of hypoglycaemic outcomes, the confirmed (with or without
symptoms) and severe categories were combined and recorded
as percentage of participants with ≥1 event and as events per
participant-year over the 12-month study period. In addition
to the threshold of ≤3.9mmol/l (≤70mg/dl), hypoglycaemic
events with a plasma glucose of <3.0mmol/l (<54mg/dl) were
analysed independently.
Data Analysis and Statistics
The efficacy measures, including insulin dose, were analysed
in the modified intention-to-treat (mITT) population (defined
as all randomized participants who received at least one dose
of study insulin and had both a baseline and at least one
post-baseline efficacy assessment during the main 6-month
on-treatment period). Analysis of change from baseline to
month 12 of key efficacy endpoints was performed using a
mixed-effects model for repeated measures.
Safety variables, including body weight, were analysed
descriptively using the safety population (defined as all partici-
pants randomized and exposed to ≥1 dose of study insulin), as
previously described [6].The change in weight from baseline to
month 12 was analysed using an analysis of covariance model
adjusted by HbA1c strata and world region. Analysis of rate
ratio based on the number of events per participant-year was
based on an overdispersed Poisson regression model adjusted
on HbA1c strata using treatment period as offset.
Results
Participant Characteristics and Disposition
Of 807 participants randomized in the initial treatment phase,
404 were assigned to Gla-300 and 403 to Gla-100. In the
Gla-100 group, 1 participant did not receive study treatment
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Figure 1. Participant flow diagram for EDITION 1. Upper portion with open boxes shows flow during the main 6-month study; shaded boxes below
indicate flow during the extension phase up to 12months. Gla-100, glargine 100U/ml; Gla-300, glargine 300U/ml; mITT, modified intention-to-treat.
*During the main 6-month on-treatment period; †Not mutually exclusive with the reason for treatment discontinuation.
and was not included in the safety and mITT populations. Two
participants who had no baseline or post-baseline efficacy end-
point during the main 6-month on-treatment period were also
excluded from the mITT population (Figure 1). Similar pro-
portions of participants in the two treatment groups completed
the initial 6-month study, 93% using Gla-300 and 92% using
Gla-100, and 89 and 88%, respectively, completed 12months.
The reasons for withdrawal did not differ between treatment
groups (Figure 1).
As previously reported [6], the demographic characteristics
at baseline were similar in both treatment groups. Overall, 53%
of participants were men, the mean [standard deviation (s.d.)]
participant age was 60 (8.6) years and the mean (s.d.) duration
of diabeteswas 16 (7.5) years.Theparticipants’mean (s.d.) body
mass index was 36.6 (6.4) kg/m2, HbA1c 8.15 (0.78)%, [65.6
(8.5)mmol/mol]), FPG 8.86 (2.90)mmol/l [159.5 (52.3)mg/dl]
and basal insulin dose 0.67 (0.27)U/kg/day.
Glycaemic Response
The improvement in glycaemic control observed at 6 months,
as measured by HbA1c (Figure 2A) and FPG (Figure 2B), was
maintained through to the end of the study in both groups. At
month 12 themean (s.d.)HbA1cwithGla-300was 7.24 (0.93)%
[55.6 (10.2)mmol/mol] and with Gla-100 it was 7.42 (0.94)%
[57.6 (10.3)mmol/mol]. The least squares (LS) mean change
from baseline was −0.86% (−9.4mmol/mol) with Gla-300
and −0.69% (−7.5mmol/mol) with Gla-100. The LS mean
difference between reductions with Gla-300 and Gla-100 at
month 12 was −0.17 (95% CI −0.30 to −0.05)%, equivalent to
−1.9 (95% CI −3.2 to −0.5)mmol/mol (p= 0.007).
A similar pattern in change of laboratory-measured
clinic-collected FPG at month 6 was observed at month 12.The
mean change from baseline was −1.6mmol/l (−29.6mg/dl)
for Gla-300 and −1.4mmol/l (−26.0mg/dl) for Gla-100; the
LS mean difference between reductions with Gla-300 versus
Gla-100 was −0.34 (95% CI −0.69 to 0.01)mmol/l [−6.1 (95%
CI −12.5 to 0.2)mg/dl; p= 0.058]. Although the overall reduc-
tions in the eight-point SMPG profile from baseline to month
12 were similar between treatments, lowering of blood glucose
at the post-dinner and bedtimemeasurements was greater with
Gla-300 (Figure S1).
Insulin Dose
During 12months of treatment, the daily basal insulin dose
in both treatment groups increased from a baseline value of
0.67U/kg (Figure 2C). The increase in dose occurred predom-
inantly during the first 12weeks, with only a gradual slight
increase between week 12 and month 12. At month 12, the
mean (s.d.) daily basal insulin dose was 1.03 (0.40)U/kg with
Gla-300 and 0.90 (0.35)U/kg with Gla-100. The mean (s.d.)
daily meal-time insulin dose at 12months was 0.55 (0.36) and
0.56 (0.38)U/kg with Gla-300 and Gla-100, respectively, and
the corresponding values for the total daily insulin dose were
1.58 (0.66) and 1.45 (0.62)U/kg. Because the mean meal-time
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Figure 2. Clinical measures (mean± standard error) during treatment by visit. (A) glycated haemoglobin (HbA1c) in the modified intention-to treat
(mITT) population. (B) Laboratory-measured clinic-collected fasting plasma glucose (FPG) in themITT population. (C) Daily basal insulin andmeal-time
insulin dose in the mITT population. (D) Weight change from baseline in the safety population. Gla-100, glargine 100U/ml; Gla-300, glargine 300U/ml.
insulin dose was similar for the two treatment groups through-
out the study, the changes in total daily insulin dose from base-
line [0.40 (0.39)U/kg with Gla-300 and 0.29 (0.39)U/kg with
Gla-100] were mainly driven by the differences in the basal
insulin doses.
Weight Change
The mean (s.d.) weight change from baseline to the last
on-treatment value was 1.2 (3.8) kg with Gla-300 and 1.4
(3.5) kg with Gla-100; LS mean difference for Gla-300 versus
Gla-100: −0.2 (95% CI −0.7 to 0.3) kg (Figure 2D).
Treatment Satisfaction
Atmonth 12, the improvements inmean (s.d.) totalDTSQ score
(0–36) from baseline for Gla-300 and Gla-100 were similar
at 2.98 (5.77) and 2.59 (5.44), respectively. Improvements in
perceived frequency of hypoglycaemia (item 3) and perceived
convenience (item 4) were also similar between groups [mean
(s.d.) changes 0.31 (1.83) vs 0.21 (1.82) and 0.52 (1.39) vs 0.48
(1.24), respectively].
Hypoglycaemia
Any Time of Day. Over 12months, fewer participants reported
≥1 confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypo-
glycaemic event, at any time of day (24 h), with Gla-300
compared with Gla-100 [86 vs 92%, respectively (Table 1);
relative risk 0.94 (95% CI 0.89–0.99)]. The cumulative number
of confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypo-
glycaemic events per participant increased at similar rates
for the two groups throughout the period of observation
(Figure 3A), and the event rates did not differ between
treatments [22 vs 21 per participant-year; rate ratio 1.06
(95% CI 0.89–1.27)].
Nocturnal. Fewer participants experienced ≥1 nocturnal
(00:00–05:59 hours) confirmed [≤3.9mmol/l (≤70mg/dl)] or
severe hypoglycaemic event with Gla-300 than with Gla-100
[54 vs 65% (Table 1); relative risk 0.84 (95% CI 0.75–0.94)],
during the 12-month study period. The cumulative number
of confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypo-
glycaemic events per participant increased more rapidly in
the Gla-100 group for the first 6months, after which the
curves were roughly parallel (Figure 3B). Annualized rates
of nocturnal confirmed [≤3.9mmol/l (≤70mg/dl)] or severe
hypoglycaemia did not differ significantly between treatments
[2.88 vs 3.19 events per participant-year; rate ratio 0.90 (95%
CI 0.70–1.16); Table 1].
Other Hypoglycaemia Categories. Fewer participants
reported ≥1 documented symptomatic hypoglycaemic event
[≤3.9mmol/l (≤70mg/dl)] in the Gla-300 group compared
with the Gla-100 group at any time of day or during the night
(Table 1).
When the more stringent hypoglycaemia threshold
[<3.0mmol/l (<54mg/dl)] was applied to the categories
of documented symptomatic and confirmed or severe hypo-
glycaemia, no significant between-treatment differences were
seen (Table 1).
Severe hypoglycaemia (any time of day) was reported by
6.7% of Gla-300- and 7.5% of Gla-100-treated participants
(Table 1).
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Table 1. Hypoglycaemia over 12months in the EDITION 1 study (safety population).
Hypoglycaemia at any time of day (24 h) Nocturnal hypoglycaemia (00:00–05:59 hours)
Gla-300
(N= 404)
Gla-100
(N= 402) RR* 95% CI
Gla-300
(N= 404)
Gla-100
(N= 402) RR* 95% CI
Total participant-years 378.91 376.37 378.91 376.37
Overall number of events 8708 8247 1146 1290
Confirmed or severe hypoglycaemia
≤3.9mmol/l (≤70mg/dl)
Participants ≥1 event, n (%) 347 (85.9) 368 (91.5) 0.94 0.89–0.99 220 (54.5) 260 (64.7) 0.84 0.75–0.94
Events, n (events per participant-year) 8464 (22.34) 7900 (20.99) 1.06 0.89–1.27 1092 (2.88) 1202 (3.19) 0.90 0.70–1.16
<3.0mmol/l (<54mg/dl)
Participants ≥1 event, n (%) 222 (55.0) 238 (59.2) 0.93 0.82–1.05 96 (23.8) 106 (26.4) 0.90 0.71–1.14
Events, n (events per participant-year) 1227 (3.24) 1050 (2.79) 1.16 0.87–1.54 234 (0.62) 229 (0.61) 1.01 0.68–1.52
Severe hypoglycaemia
Participants ≥1 event, n (%) 27 (6.7) 30 (7.5) 0.90 0.54–1.48 10 (2.5) 13 (3.2) 0.77 0.34–1.73
Events, n (events per participant-year) 72 (0.19) 54 (0.14) 1.32 0.46–3.81 15 (0.04) 18 (0.05) 0.83 0.29–2.38
Documented symptomatic hypoglycaemia
≤3.9mmol/l (≤70mg/dl)
Participants ≥1 event, n (%) 302 (74.8) 333 (82.8) 0.90 0.84–0.97 180 (44.6) 230 (57.2) 0.78 0.68–0.89
Events, n (events per participant-year) 4573 (12.07) 4404 (11.70) 1.03 0.84–1.27 695 (1.83) 938 (2.49) 0.74 0.56–0.97
<3.0mmol/l (<54mg/dl)
Participants ≥1 event, n (%) 186 (46.0) 204 (50.7) 0.91 0.79–1.05 80 (19.8) 92 (22.9) 0.87 0.66–1.13
Events, n (events per participant-year) 831 (2.19) 784 (2.08) 1.05 0.78–1.43 179 (0.47) 191 (0.51) 0.93 0.59–1.47
Asymptomatic hypoglycaemia
≤3.9mmol/l (≤70mg/dl)
Participants ≥1 event, n (%) 285 (70.5) 295 (73.4) 0.96 0.88–1.05 118 (29.2) 125 (31.1) 0.94 0.76–1.16
Events, n (events per participant-year) 3694 (9.75) 3307 (8.79) 1.11 0.86–1.43 368 (0.97) 237 (0.63) 1.54 0.96–2.47
<3.0mmol/l (<54mg/dl)
Participants ≥1 event, n (%) 89 (22.0) 82 (20.4) 1.08 0.83–1.41 17 (4.2) 16 (4.0) 1.06 0.54–2.06
Events, n (events per participant-year) 311 (0.82) 201 (0.53) 1.54 0.93–2.53 35 (0.09) 19 (0.05) 1.82 0.77–4.31
Gla-100, glargine 100U/ml; Gla-300, glargine 300U/ml; CI, confidence interval.
*RR, relative risk for participants with ≥1 hypoglycaemic event and rate ratio for hypoglycaemic events per participant-year.
Adverse Events
Overall, 72% of participants in the Gla-300 and 69% in
the Gla-100 treatment groups reported treatment-emergent
adverse events (Table S1). Injection site reactions were reported
by 12 (3.0%) and 6 (1.5%) participants in the Gla-300 and
Gla-100 groups, respectively. Serious adverse events occurred
in 13% of participants using Gla-300 and 15% using Gla-100.
Discontinuation of treatment because of an adverse event
occurred in 2.2 and 3.5% of participants using Gla-300 and
Gla-100. Six participants had serious treatment-emergent
adverse events with fatal outcome during the study [2 par-
ticipants in the Gla-300 group (bronchopneumonia, n= 1;
bronchogenic carcinoma, n= 1) and four in the Gla-100 group
(intoxication with medication after recurrent depression,
n= 1; myocardial infarction, n= 1; worsening chronic heart
failure, n= 1; acute pulmonary arrest, n= 1)]. Three additional
participants died after discontinuation of study medication [2
participants in the Gla-300 group (infective thrombosis, n= 1;
pulmonary embolism, n= 1) and one in the Gla-100 group
(unknown cause)]. None of these events were considered
related to study medication.
Discussion
The results of the 6-month extension of the EDITION 1 study
are largely consistent with the observations from the core
6-month study [6]. Adherence to both Gla-300 and Gla-100
as part of a basal-bolus treatment regimen continued to be
very good, with nearly 90% of enrolled participants completing
12months of follow-up. Both regimens provided sustained
glycaemic control with mean levels at 12months (7.24% with
Gla-300 and 7.42% with Gla-100) that were similar to those
observed at the end of 6months [6]. The present observations
also confirm that a 14%higher dose of Gla-300 [representing an
8% increase in total average insulin dose (basal plus meal-time
insulin)] compared with Gla-100 was required to maintain
these levels of glycaemic control, without leading to a higher
risk of hypoglycaemia. The cause of the difference in insulin
dosage is not known; however, as the main active molecule
circulating after injection of both Gla-300 and Gla-100 is the
same M1 metabolite [12,13], an effect at the subcutaneous
depot seems most likely. Potentially, a longer residence time
for Gla-300 in the subcutaneous space, which is consistent
with the more stable and prolonged pharmacokinetic and
pharmacodynamic profiles [5], might lead to an increase of
enzymatic inactivation at that injection site. In addition, the
slight further increase of dose of Gla-300 during the extension
period, when the study participants were more responsible
for dosing decisions, is consistent with the participants having
greater confidence in increasing the dose at given levels of
glucose.
Some additional observations from this study extend the
findings of the earlier report of 6-month results. At the end of
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Figure 3. Cumulative mean numbers of confirmed [≤3.9mmol/l (≤70mg/dl)] or severe hypoglycaemic events per participant during the 12-month study
period (safety population). (A) Events occurring at any time of day (24 h). (B) Nocturnal events (00:00–05:59 hours). Gla-100, glargine 100U/ml; Gla-300,
glargine 300U/ml [Correction added on May 29: In Figure 3A, the values of Gla-100 and Gla-300 were previously incorrect and these have now been
amended in this version].
the first 6months there was a between-treatment difference in
risk of hypoglycaemia, especially at night, favouring Gla-300.
The lower risk of nocturnal hypoglycaemia was maintained
over the 12-month period, although the difference was attenu-
ated over time. Overall, the numbers of participants affected by
hypoglycaemia at any time of the day were equivalent or lower
with Gla-300, depending on the category of hypoglycaemia
reported. The annualized rates of hypoglycaemia were simi-
lar or slightly higher with Gla-300 than with Gla-100 during
the full extension period across the categories, mostly owing to
more hypoglycaemic events being reported during the daytime.
Insufficient adjustment of the meal-time insulin dose may have
influenced the frequency of daytime hypoglycaemic events and
contributed to the observed rates of hypoglycaemia in the
treatment groups.
Although the reduction of HbA1c from baseline showed no
tendency to differ between the groups treated with Gla-300
or Gla-100 for the first 6months, by the end of the 12months
a small but significant difference favouring Gla-300 was
found [LS mean difference −0.17 (95% CI −0.30 to −0.05)%,
p= 0.007]. Examination of the HbA1c patterns over time
(Figure 2A) suggests that the less intensive follow-up of
participants in the extension period led to a modest initial
worsening of control in both arms at 9months, and this
persisted at 12months with Gla-100 but not with Gla-300. The
patterns of HbA1c were consistent with similar trends for FPG
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[LS mean difference −0.34 (95% CI −0.69 to 0.01)mmol/l;
p= 0.058] at month 12, and also in the late-evening measure-
ments on the eight-point glucose profiles at month 12. Thus,
waning of the lower risk of hypoglycaemia with Gla-300 during
the second 6months of treatment occurred concurrently with
apparent improvement in glycaemic control. These differences
in glycaemic control are modest, and the period of extension
was still limited; however, they do suggest that, as duration
of treatment increased, the advantage of Gla-300 in terms of
risk of hypoglycaemia may have improved the participants’
ability to make appropriate decisions regarding timing and
adjustment of basal and meal-time insulin doses. Further
study of the relationships between the frequency of nocturnal
hypoglycaemia during titration of Gla-300, risk of daytime
hypoglycaemia, and attained HbA1c seems warranted.
The tolerability of both Gla-300 and Gla-100 continued to
be very good throughout the 12-month period, with similar
numbers of participants experiencing adverse events and no
new problems observed. This was not unexpected, given that
Gla-300 and Gla-100 are different formulations of the same
molecule with the same active circulating metabolite [12,13].
The high proportion of participants completing the extension
study further supports the tolerability of both Gla-300 and
Gla-100.
Beyond the limitations discussed in the initial 6-month study
report, which are also applicable to the 12-month study [6],
notably the unavoidable open-label nature of treatment, there
is additional potential for biased reporting of safety and efficacy
outcomes in an extension study.
In summary, in this challenging population of people with
obesity, long duration of T2DMand the need for both basal and
meal-time insulin treatment, the improved glycaemic control
reported in the 6-month studywasmaintained up to 12months,
without any new safety concerns. Whether even longer-term
treatment with Gla-300 would lead to better glycaemic control
with equivalent or lower frequency of hypoglycaemia in this or
other populations is unknown, butmight be examined in future
investigations.
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